FNCH Finch Therapeutics Group, Inc. Stock Quote

FNCH [NASD]

Index	-	P/E	-	EPS (ttm)	-	Insider Own	6.80%	Shs Outstand	47.23M	Perf Week	-2.23%
Market Cap	617.15M	Forward P/E	-	EPS next Y	-7.79	Insider Trans	6.38%	Shs Float	24.07M	Perf Month	-6.40%
Income	-	PEG	-	EPS next Q	-0.28	Inst Own	14.30%	Short Float	1.41%	Perf Quarter	-5.93%
Sales	9.48M	P/S	65.10	EPS this Y	-89.60%	Inst Trans	-	Short Ratio	4.16	Perf Half Y	-
Book/sh	5.07	P/B	2.60	EPS next Y	-17.60%	ROA	-	Target Price	-	Perf Year	-
Cash/sh	4.12	P/C	3.20	EPS next 5Y	-	ROE	-	52W Range	11.56 - 22.50	Perf YTD	-38.23%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	42.00%	52W High	-41.47%	Beta	-
Dividend %	-	Quick Ratio	17.20	Sales past 5Y	-	Gross Margin	-	52W Low	13.93%	ATR	1.28
Employees	131	Current Ratio	17.20	Sales Q/Q	98.30%	Oper. Margin	-	RSI (14)	40.71	Volatility	7.68% 8.16%
Optionable	No	Debt/Eq	0.01	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.32	Prev Close	14.18
Shortable	Yes	LT Debt/Eq	0.01	Earnings	-	Payout	-	Avg Volume	81.75K	Price	13.17
Recom	1.00	SMA20	-11.07%	SMA50	-9.53%	SMA200	-10.77%	Volume	26,210	Change	-7.12%

Apr-13-21

Initiated

Jefferies

Buy

$29

Apr-13-21

Initiated

Evercore ISI

Outperform

$34

Apr-13-21

Initiated

BofA Securities

Buy

$25

Jun-28-21 07:00AM	Finch Therapeutics Added to Russell 2000 and Russell 3000 Indexes GlobeNewswire
May-28-21 07:00AM	Finch Therapeutics to Present at Upcoming Virtual Investor Conferences GlobeNewswire -5.26%
May-13-21 07:00AM	Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates GlobeNewswire
May-06-21 07:00AM	Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference GlobeNewswire
Apr-27-21 07:00AM	Finch Therapeutics Appoints Susan E. Graf to Board of Directors GlobeNewswire
Mar-19-21 04:25PM	Three Biotechs, plus a Marijuana Lender, Open for Trading Barrons.com
Mar-18-21 10:32PM	Finch Therapeutics Announces Pricing of Upsized Initial Public Offering GlobeNewswire

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FERRANTE DOMENIC J	Director	Mar 23	Buy	17.00	102,941	1,749,997	636,195	Mar 25 06:04 PM
SMISEK JEFFERY A	Director	Mar 23	Buy	17.00	88,235	1,499,995	1,694,541	Mar 25 06:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience